Squarepoint Ops LLC Erasca, Inc. Transaction History

Squarepoint Ops LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.79 - $2.63 $169,743 - $249,400	94,829 Added 169.35%	150,826 $355,000
Q1 2024 May 15, 2024	SELL	$1.67 - $2.55 $54,219 - $82,790	-32,467 Reduced 36.7%	55,997 $115,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $118,294 - $176,379	70,835 Added 401.81%	88,464 $188,000
Q2 2023 Aug 14, 2023	SELL	$2.57 - $3.3 $1.26 Million - $1.62 Million	-491,836 Reduced 96.54%	17,629 $48,000
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $697,650 - $1.13 Million	254,617 Added 99.91%	509,465 $1.53 Million
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $991,358 - $2.18 Million	254,848 New	254,848 $1.1 Million
Q2 2022 Aug 15, 2022	BUY	$4.58 - $8.72 $175,194 - $333,557	38,252 Added 333.15%	49,734 $277,000
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $98,745 - $177,741	11,482 New	11,482 $99,000

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $310M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.